Ocular Therapeutix reported Phase 3 results showing its Axpaxli formulation maintained vision longer than a low‑dose regimen of Regeneron’s Eylea, meeting the trial’s primary durability and maintenance endpoints. The trial showed higher proportions of patients maintaining vision at nine months and one year with a single injection of Axpaxli versus the low‑dose comparator. Topline figures released by the company and reported by STAT indicate 74% vs 56% at nine months and 66% vs 44% at one year (Axpaxli vs low‑dose Eylea). Analysts and clinicians noted the superiority versus a low‑dose active control but warned that comparisons to full‑dose standard of care and commercial positioning will determine market impact. Ocular will publish detailed data and engage regulators; the company and investors will assess whether the durability gains translate into a competitive commercial profile in a crowded wet‑AMD market.